Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical citrate vs nafamostat mesylate anticoagulation in CRRT
ChiCTR2300078946Phase 4Recruiting
- Sponsor
- Beijing Luhe Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute kidney failure (AKF) comparing NM group (nafamostat mesylate) with RCA group (regional citrate) (2 arms). Primary endpoints: Filter service life and number of filters used within 72 hours and Bleeding after treatment with CRRT anticoagulants. Started Dec 2023; status: recruiting.
02
Drugs
Nafabelltantrisodium citrate
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ChiCTR2300078946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078946.